gene

BRAF

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BRAF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

594Connections

0Hypotheses

0Analyses

50Outgoing

50Incoming

0Experiments

0Debates

Summary

RAF kinase in MAPK signaling - neuronal development, synaptic plasticity, and neurodegeneration

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	BRAF
Full Name	B-Raf Proto-Oncogene, Serine/Threonine Kinase
Aliases	RAF kinase in MAPK signaling
Protein Family	RAF serine/threonine kinases
Protein Type	Serine/Threonine Kinase
Function	BRAF is a serine/threonine-protein kinase that serves as a key intermediate in the RAS-RAF-MEK-ERK signaling cascade.
Molecular Weight	84.5 kDa
Amino Acids	766 aa
Pathways	MAPK, mapk
UniProt ID	[P15056](https://www.uniprot.org/uniprot/P15056)
GeneCards	BRAF
Human Protein Atlas	BRAF
Associated Diseases	AD, Als, Ameloblastoma, cancer
Known Drugs/Compounds	dabrafenib, encorafenib + cetuximab, SORAFENIB, TRAMETINIB
Interactions	ABCB1, AGING, AKT, AKT3, ALZHEIMER, AMYLOID
KG Connections	594 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

BRAF — B-Raf Proto-Oncogene, Serine/Threonine Kinase

gene · 1422 words

→

Pathway Diagram

flowchart TD
    BRAF["BRAF
Proto-oncogene"]
    MAPK["MAPK Pathway
Signal Transduction"]
    KIAA1549["KIAA1549
Fusion Partner"]
    
    ALS["Amyotrophic Lateral
Sclerosis (ALS)"]
    MS["Multiple Sclerosis
(MS)"]
    NEURODEGENERATION["Neurodegeneration
Process"]
    
    GLIOMA["Glioma
Brain Tumor"]
    GLIOBLASTOMA["Glioblastoma
Aggressive Glioma"]
    PEDIATRIC_GLIOMA["Pediatric Low-grade
Gliomas"]
    
    SENESCENCE["Cellular
Senescence"]
    TUMOR_GROWTH["Tumor Growth
 and Progression"]
    
    THERAPEUTIC_TARGET["Therapeutic
Target"]
    BIOMARKER["Disease
Biomarker"]
    
    BRAF -->|"activates"| MAPK
    KIAA1549 -->|"forms fusion with"| BRAF
    
    BRAF -->|"activates"| ALS
    BRAF -->|"activates"| MS
    BRAF -->|"associated with"| NEURODEGENERATION
    
    BRAF -->|"associated with"| GLIOMA
    BRAF -->|"associated with"| GLIOBLASTOMA
    BRAF -->|"biomarker for"| PEDIATRIC_GLIOMA
    
    BRAF -->|"promotes"| TUMOR_GROWTH
    BRAF -->|"therapeutic target for"| SENESCENCE
    
    BRAF --> THERAPEUTIC_TARGET
    BRAF --> BIOMARKER
    
    MAPK -->|"drives"| TUMOR_GROWTH
    MAPK -->|"contributes to"| NEURODEGENERATION
    
    style BRAF fill:#006494
    style MAPK fill:#4a1a6b
    style KIAA1549 fill:#4a1a6b
    style ALS fill:#ef5350
    style MS fill:#ef5350
    style NEURODEGENERATION fill:#ef5350
    style GLIOMA fill:#ef5350
    style GLIOBLASTOMA fill:#ef5350
    style PEDIATRIC_GLIOMA fill:#5d4400
    style SENESCENCE fill:#ef5350
    style TUMOR_GROWTH fill:#ef5350
    style THERAPEUTIC_TARGET fill:#1b5e20
    style BIOMARKER fill:#5d4400

Outgoing (439)

Target	Relation	Type	Str
Tumor	therapeutic_target	disease	1.00
Cancer	therapeutic_target	disease	1.00
Als	activates	disease	1.00
encorafenib + cetuximab	therapeutic_target	drug	0.95
Tumor	activates	disease	0.95
Cancer	inhibits	disease	0.95
Cancer	activates	disease	0.95
MAPK Pathway	activates	pathway	0.95
Cancer	associated_with	disease	0.95
RAS-MAPK signaling pathway	involved_in	pathway	0.95
MAPK pathway	activates	pathway	0.95
Langerhans Cell Histiocytosis	associated_with	disease	0.92
mitogen-activated protein kinase pathway	activates	pathway	0.92
CRAF	interacts_with	protein	0.90
MAP2K1	upstream_of	protein	0.90
BRAIN TUMOURS	associated_with	entity	0.90
pilocytic astrocytoma	drives	disease	0.90
Mapk	activates	pathway	0.90
Ameloblastoma	associated_with	disease	0.85
Acute Myeloid Leukemia	drives	disease	0.85
Als	inhibits	disease	0.85
hairy cell leukemia	biomarker_for	disease	0.85
Als	associated_with	disease	0.85
Als	therapeutic_target	disease	0.85
AMELOBLASTOMA	associated_with	disease	0.85
oxidative stress response	participates_in	pathway	0.80
Pilocytic Astrocytomas	associated_with	disease	0.80
Therapy-Related Acute Myeloid Leukemia	associated_with	disease	0.80
Chronic Myelomonocytic Leukemia	associated_with	disease	0.80
NF1	activates	gene	0.80
GENES	activates	gene	0.80
CANCER	associated_with	gene	0.80
Tumor	inhibits	disease	0.75
Colorectal Cancer	associated_with	disease	0.75
Melanoma	associated_with	disease	0.75
Carcinoma	therapeutic_target	disease	0.75
Glioma	therapeutic_target	disease	0.75
Lung Cancer	therapeutic_target	disease	0.75
Colorectal Cancer	activates	disease	0.75
MAPK	activates	pathway	0.72
Wnt	activates	pathway	0.70
CANCER	therapeutic_target	gene	0.70
MAPK signaling	participates_in	pathway	0.70
DNA	associated_with	gene	0.70
Mtor	therapeutic_target	pathway	0.70
Differentiation	activates	pathway	0.70
Epigenetic	associated_with	pathway	0.70
Mapk	associated_with	pathway	0.70
RAS	activates	gene	0.70
Erk Signaling	activates	pathway	0.70

Incoming (155)

Source	Relation	Type	Str
dabrafenib	inhibits	drug	0.95
Myeloid Precursor	expressed_in	cell_type	0.85
MAPK	interacts_with	gene	0.80
ERK	activates	gene	0.80
ERK	therapeutic_target	gene	0.80
DNMT3A	interacts_with	gene	0.75
SRSF2	interacts_with	gene	0.75
ASXL1	interacts_with	gene	0.75
TET2	interacts_with	gene	0.75
KIAA1549	interacts_with	gene	0.72
KRAS	interacts_with	gene	0.70
CANCER	inhibits	gene	0.70
PTEN	associated_with	gene	0.70
ERK	inhibits	gene	0.70
PTEN	therapeutic_target	gene	0.70
ERK	associated_with	gene	0.70
ASTROCYTE	interacts_with	cell_type	0.65
ASTROCYTE	causes	cell_type	0.65
ASTROCYTE	treats	cell_type	0.65
ASTROCYTES	treats	cell_type	0.65
EGFR	expressed_in	gene	0.60
MAF	activates	gene	0.60
AKT	inhibits	gene	0.60
PIK3CA	inhibits	gene	0.60
PTEN	inhibits	gene	0.60
OVERVIEW	inhibits	gene	0.60
MTOR	inhibits	gene	0.60
NEURODEGENERATION	inhibits	gene	0.60
KRAS	activates	gene	0.60
ROS	activates	gene	0.60
BRAFV600E	inhibits	gene	0.60
DNA	expressed_in	gene	0.60
CDK1	therapeutic_target	gene	0.60
AGING	activates	gene	0.60
MICROGLIA	therapeutic_target	gene	0.60
P53	therapeutic_target	gene	0.60
CANCER	associated_with	gene	0.60
ASTROCYTES	inhibits	gene	0.60
RAS	associated_with	gene	0.60
IRS1	regulates	gene	0.60
KIAA1549	inhibits	gene	0.60
GENES	expressed_in	gene	0.60
APOPTOSIS	contributes_to	gene	0.60
TERT	activates	gene	0.60
BRD4	therapeutic_target	gene	0.60
NFE2L2	regulates	gene	0.60
SMO	therapeutic_target	gene	0.60
EZH2	therapeutic_target	gene	0.60
DYRK1A	associated_with	gene	0.60
AXL	activates	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning BRAF in their description or question text

No additional research found